
Mogamulizumab
CAS No. 1159266-37-1
Mogamulizumab( —— )
Catalog No. M36717 CAS No. 1159266-37-1
Mogamulizumab (KW-0761) is a monoclonal antibody targeting T cell CC chemokine receptor 4.
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
2MG | 724 | Get Quote |
![]() ![]() |
5MG | 938 | Get Quote |
![]() ![]() |
10MG | 1311 | Get Quote |
![]() ![]() |
25MG | 1822 | Get Quote |
![]() ![]() |
50MG | 2567 | Get Quote |
![]() ![]() |
100MG | 3411 | Get Quote |
![]() ![]() |
500MG | Get Quote | Get Quote |
![]() ![]() |
1G | Get Quote | Get Quote |
![]() ![]() |
Biological Information
-
Product NameMogamulizumab
-
NoteResearch use only, not for human use.
-
Brief DescriptionMogamulizumab (KW-0761) is a monoclonal antibody targeting T cell CC chemokine receptor 4.
-
DescriptionMogamulizumab (KW-0761) is a recombinant anti-CCR4 monoclonal antibody (MAb). Mogamulizumab can eliminate tumor cells by antibody-dependent cellular cytotoxicity (ADCC). Mogamulizumab can be used in the research of cancers, adult T-cell leukemia/lymphoma (ATLL), cutaneous T-cell lymphoma (CTCL).
-
In VitroMogamulizumab (10 μg/mL, 24 h) induces ADCC activity against CCR4-positive cell lines (SNT8, SNT16, SNK6, and KAI3) in the presence of PBMCs.Mogamulizumab (10 μg/mL, 3 days) reduces the human T-lymphotropic virus type 1 (HTLV-1) proviral load and inhibits spontaneous proliferation in PBMCs from patients with HTLV-1–associated myelopathy/tropical spastic paraparesis (HAM/TSP).Mogamulizumab (1 μg/mL, 5 days) eliminates the CD4+CCR4+ T cells in cultured PBMCs from patients with HAM/TSP.
-
In VivoMogamulizumab (1 mg/kg, i.p., twice per week for 4 weeks) together with PBMC transplantation inhibits the growth of EBV-positive NK-cell lymphomas in a murine xenograft model.Mogamulizumab (0.1 mg/kg, i.v., every other day) together with canine PBMCs (every fourth day)), inhibits tumor growth in canine bladder cancer-engrafted mouse model.Mogamulizumab (0.01-1 mg/kg, i.v.) reduces circulating CD4+CCR4+ T cells, with no adverse effect in dogs.Animal Model:Murine xenograft model, constructed by using the immunodeficient NOG mouse and the EBV-positive NK-cell lymphoma cell line (SNK6)Dosage:1 mg/kg Administration: Intraperitoneal injection (i.p.), together with PBMC transplantation; twice per week for 4 weeks.Result:Suppressed Tumor growth with vacuolar degeneration.
-
Synonyms——
-
PathwayAutophagy
-
TargetCXCR
-
RecptorCXCR
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1159266-37-1
-
Formula Weight
-
Molecular Formula——
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Duvic M, et al. Mogamulizumab for the treatment of cutaneous T-cell lymphoma: recent advances and clinical potential. Ther Adv Hematol. 2016 Jun;7(3):171-4.?
molnova catalog



related products
-
Solasodine
Solasodine is a potentially useful precursor for steroidal compounds and hormones with anticonvulsant and central nervous system depressant activities.
-
VUF11207 fumarate
VUF11207 fumarate is an agonist of CXCR7 and a high-potency ligand of CXCR7 (pKi: 8.1).
-
Ajmaline
Ajmaline is a class Ia anti-arrhythmic compound that is widely used for the diagnosis of Brugada syndrome and the acute treatment of atrial or ventricular tachycardia.